An announcement from Tryptamine Therapeutics ( (AU:TYP) ) is now available.
Tryptamine Therapeutics has established a framework for a groundbreaking clinical trial to treat Binge Eating Disorder (BED) using its TRP-8803 formulation. The trial, set to begin in the June quarter, will involve 12 patients and aims to assess the safety and efficacy of TRP-8803, which has shown promising results in reducing binge eating episodes. This initiative follows positive interim data from a previous study and positions the company as a pioneer in addressing BED, a prevalent eating disorder in the US and Australia. Additionally, Tryptamine Therapeutics presented at the Biotech Showcase 2025, gaining exposure to potential strategic partners and investors, and announced changes in its corporate structure, including a new auditor and company secretary.
More about Tryptamine Therapeutics
Tryptamine Therapeutics Limited is a clinical-stage biopharmaceutical company focused on developing TRP-8803, a proprietary psilocin-based, IV-infused formulation with neuroplastic benefits. The company is engaged in the clinical development of treatments for conditions such as Binge Eating Disorder (BED), leveraging its expertise in neuropharmacology.
YTD Price Performance: -20.0%
Average Trading Volume: 1,694,599
Technical Sentiment Signal: Buy
Current Market Cap: A$46.05M
For detailed information about TYP stock, go to TipRanks’ Stock Analysis page.